A Phase 1, Double-Blind, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RC-01 for Injection in Healthy Adult Subjects
Latest Information Update: 30 May 2019
At a glance
- Drugs RC 01 (Primary)
- Indications Bacterial infections; Respiratory tract infections
- Focus Adverse reactions
- Sponsors Recida Therapeutics
Most Recent Events
- 24 May 2019 Status changed from recruiting to discontinued.
- 01 Apr 2019 Status changed from not yet recruiting to recruiting, according to a Recida Therapeutics media release.
- 14 Feb 2019 New trial record